MX2018013715A - Composiciones acuosas de capsaicinoides que comprenden un analgesico y un vehiculo acuoso, y uso de las mismas para el tratamiento del dolor. - Google Patents

Composiciones acuosas de capsaicinoides que comprenden un analgesico y un vehiculo acuoso, y uso de las mismas para el tratamiento del dolor.

Info

Publication number
MX2018013715A
MX2018013715A MX2018013715A MX2018013715A MX2018013715A MX 2018013715 A MX2018013715 A MX 2018013715A MX 2018013715 A MX2018013715 A MX 2018013715A MX 2018013715 A MX2018013715 A MX 2018013715A MX 2018013715 A MX2018013715 A MX 2018013715A
Authority
MX
Mexico
Prior art keywords
capsaicinoid
formulations
treatment
corticosteroid
administration
Prior art date
Application number
MX2018013715A
Other languages
English (en)
Inventor
A Birbara Charles
COUGHLIN Mary
J Birbara Philip
Bucks Daniel
Original Assignee
Vizuri Health Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vizuri Health Sciences Llc filed Critical Vizuri Health Sciences Llc
Publication of MX2018013715A publication Critical patent/MX2018013715A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/738—Cross-linked polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En este documento se dan a conocer formulaciones de capsaicinoides y métodos de tratamiento los cuales se pueden utilizar para tratar/atenuar el dolor en mamíferos. Típicamente, la administración es por vía de una inyección en un sitio discreto para proporcionar alivio al dolor durante un período de tiempo prolongado. Las formulaciones se administran en un vehículo farmacéuticamente aceptable. Las formulaciones incluyen un agente analgésico en una cantidad suficiente para atenuar los efectos de quemadura e hiperalgésicos de la administración de capsaicinoides. La invención también incluye un método para tratar el dolor por medio de la administración de un corticosteroide seguido por la administración de un capsaicinoide.
MX2018013715A 2012-11-12 2015-05-11 Composiciones acuosas de capsaicinoides que comprenden un analgesico y un vehiculo acuoso, y uso de las mismas para el tratamiento del dolor. MX2018013715A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261725161P 2012-11-12 2012-11-12

Publications (1)

Publication Number Publication Date
MX2018013715A true MX2018013715A (es) 2019-07-29

Family

ID=49880927

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015005879A MX362804B (es) 2012-11-12 2013-11-12 Composiciones acuosas de capsaicinoides que comprenden un analgésico y un vehículo acuoso, y uso de las mismas para el tratamiento del dolor.
MX2018013715A MX2018013715A (es) 2012-11-12 2015-05-11 Composiciones acuosas de capsaicinoides que comprenden un analgesico y un vehiculo acuoso, y uso de las mismas para el tratamiento del dolor.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015005879A MX362804B (es) 2012-11-12 2013-11-12 Composiciones acuosas de capsaicinoides que comprenden un analgésico y un vehículo acuoso, y uso de las mismas para el tratamiento del dolor.

Country Status (9)

Country Link
US (2) US20140142073A1 (es)
EP (2) EP2916817B1 (es)
JP (1) JP6695140B2 (es)
KR (2) KR20150084996A (es)
CN (1) CN105101949A (es)
AU (1) AU2013341380B2 (es)
CA (1) CA2891218A1 (es)
MX (2) MX362804B (es)
WO (1) WO2014075084A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150133561A1 (en) * 2013-11-12 2015-05-14 Vizuri Health Sciences Llc Aqueous based capsaicinoid formulations and methods of manufacture and use
KR102073258B1 (ko) 2014-04-15 2020-02-04 비쭈리 헬스 사이언스 엘엘씨 통증 완화용 국소 조성물, 제조방법 및 용도
JP6948762B2 (ja) * 2015-10-16 2021-10-13 株式会社マンダム Ｔｒｐｖ１活性抑制剤作用増幅用組成物
AU2017210315A1 (en) * 2016-01-22 2018-08-16 Centrexion Therapeutics Corporation Capsaicin sequential dosing method for treatment of morton's neuroma pain
CN110035740B (zh) * 2016-11-02 2023-08-04 中枢疗法公司 稳定的水性辣椒素可注射制剂及其医学用途
CN111201015A (zh) * 2017-07-20 2020-05-26 中枢疗法公司 使用辣椒素治疗疼痛的方法和组合物
EP3697402A1 (en) * 2017-10-20 2020-08-26 aXichem AB Synthetic capsaicin analogues as bioenhancers
CA3109932A1 (en) * 2018-08-24 2020-02-27 Centrexion Therapeutics Corporation Capsaicin sequential dosing method for treatment of knee joint pain
CN112691091A (zh) * 2021-01-09 2021-04-23 胡宝贤 低浓度石炭酸的新应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599342A (en) * 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4702916A (en) * 1985-12-03 1987-10-27 Warner-Lambert Company Analgesic stick compositions
JPS63130540A (ja) * 1986-11-18 1988-06-02 Sunstar Inc 鎮痛用組成物
JPH0621063B2 (ja) * 1986-12-06 1994-03-23 サンスタ−株式会社 歯科用鎮痛剤組成物
JP2001515492A (ja) 1997-03-13 2001-09-18 エヌ． キャンベル，ジェイムズ カプサイシンまたはカプサイシンアナログを含有する組成物および局所麻酔
JP3022541B1 (ja) * 1999-01-11 2000-03-21 株式会社ヘルスサイエンスセンター 外用剤
US6573302B1 (en) * 1999-09-29 2003-06-03 Medical Merchandising, Inc. Cream utilizing capsaicin
US6579543B1 (en) * 2002-02-22 2003-06-17 Jackie H. McClung Composition for topical application to skin
US20040161481A1 (en) 2002-12-18 2004-08-19 Algorx Administration of capsaicinoids
PT1605956E (pt) 2002-12-18 2016-03-09 Centrexion Therapeutics Corp Administração de capsaicinóides para o tratamento da osteoartrite
EA008705B1 (ru) 2003-04-08 2007-06-29 Алгоркс Фармасьютикалз, Инк. Получение и очистка синтетического капсаицина
EP1763370B1 (en) 2004-06-02 2015-04-29 NeurogesX Inc. Formulations comprising capsaicin, a local anesthetic and/or an antipruritic agent for the treatment of pain
JP2006298944A (ja) * 2004-11-05 2006-11-02 Maruishi Pharmaceutical Co Ltd インスリン様成長因子−１分泌促進剤
US20060148903A1 (en) 2004-11-24 2006-07-06 Algorx Pharmaceuticals, Inc. Capsaicinoid gel formulation and uses thereof
ES2355109T3 (es) * 2004-12-22 2011-03-22 Mestex Ag Mezcla de un agonista de receptor de vainilloide con una sustancia inhibidora de la regeneración nerviosa, su utilización para la fabricación de un analgésico y procedimiento de aplicación de este fármaco.
US8703741B2 (en) 2004-12-28 2014-04-22 Mestex Ag Method of treating articular pain using a vanilloid receptor agonist together with a glycosaminoglycan or proteoglycan
US20070098660A1 (en) * 2005-10-27 2007-05-03 Jim Taneri Methods and compositions for epilation
US8623335B2 (en) * 2007-09-10 2014-01-07 Tauna Ann Waddington Scar and rosacea and other skin care treatment composition and method
US8158682B2 (en) 2008-09-12 2012-04-17 Vallinex, Inc. Instillation administration of capsaicinoids for the treatment of pain
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
NZ602405A (en) * 2010-03-12 2014-12-24 Allergan Ind Sas A fluid composition comprising a hyaluronan polymer and mannitol for improving skin conditions
JP6105475B2 (ja) * 2010-10-22 2017-03-29 ヴィズリ・ヘルス・サイエンスィズ・エルエルシー 可溶性の乏しい化合物の可溶性を増大させる方法ならびにそのような化合物の配合物を作る、および用いる方法
KR101769010B1 (ko) 2011-09-09 2017-08-17 비쭈리 헬스 사이언스 엘엘씨 Trpv1 선택적 작용제를 포함하는 통증 완화 조성물, 및 이의 제조방법 및 용도

Also Published As

Publication number Publication date
MX2015005879A (es) 2016-02-05
EP2916817A2 (en) 2015-09-16
JP6695140B2 (ja) 2020-05-20
KR20200119351A (ko) 2020-10-19
MX362804B (es) 2019-02-14
JP2015536998A (ja) 2015-12-24
AU2013341380B2 (en) 2018-04-26
EP3446680A1 (en) 2019-02-27
CN105101949A (zh) 2015-11-25
CA2891218A1 (en) 2014-05-15
EP2916817B1 (en) 2018-09-12
WO2014075084A2 (en) 2014-05-15
WO2014075084A3 (en) 2014-07-10
US20140142073A1 (en) 2014-05-22
AU2013341380A1 (en) 2014-05-15
US20190022110A1 (en) 2019-01-24
KR20150084996A (ko) 2015-07-22
AU2013341380A2 (en) 2015-10-22

Similar Documents

Publication Publication Date Title
MX2018013715A (es) Composiciones acuosas de capsaicinoides que comprenden un analgesico y un vehiculo acuoso, y uso de las mismas para el tratamiento del dolor.
MX2016006179A (es) Formulaciones de capsaicinoides basadas en agua y metodos de manufactura y uso.
MX2016005532A (es) Metodos para usar oxido nitrico en un estado de plasma para tratar condiciones medicas y enfermedades.
MX2014004548A (es) Metodos para tratar pacientes pediatricos usando dexmedetomidina.
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
WO2013078440A3 (en) Enhanced treatment regimens using mtor inhibitors
GB2491327A (en) Delayed prolonged drug delivery
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
GB2491328A (en) Immediate/delayed drug delivery
BR112016007946A2 (pt) combinação farmacêutica, usos da mesma, de plinabulina e de composição, kits ou mistura e método para tratar e/ou prevenir câncer
MX2010012860A (es) Metodos para tratar cancer del sistema nervioso central.
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
MX2015003035A (es) Administracion de inhibidores de acetilcolinesterasa para mitigar la paralisis inducida por neurotoxinas y el bloqueo neuromuscular residual.
MX2016002479A (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris.
MX367070B (es) Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
IN2014DN08598A (es)
JOP20200031A1 (ar) طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة
MX2015016418A (es) Dihidroetorfina para proporcionar el alivio del dolor y la anestesia.
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders
MX2010013790A (es) Composiciones y metodos para tratar inflamacion de corneas.
TW201613599A (en) Use of composition for manufacture of medicament for suppressing androgen receptor related function and treatment of androgen receptor related disease
MX358512B (es) Uso de (r)-7cloro-n-(quinuclidin-3-il) benzo[b] tiofeno-2-carboxamida o una sal farmacéuticamente aceptable de la misma para preparar una composición farmacéutica en el tratamiento de una disfunción cognitiva.
NZ760033A (en) Methods to treat opioid use disorder
EA201491836A1 (ru) Способы лечения рака с использованием ингибитора pi3k и ингибитора mek